Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PHAT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Vonoprazan Fumarate And Amoxicillin FDA approved May 2022 · Voquezna Dual Pak |
H Pylori Infection | Phase 4 · NCT07224035 | Completed |
| Vonoprazan FDA approved Nov 2023 · Voquezna |
Symptomatic Non-erosive Gastroesophageal Reflux Disease | Phase 3 · NCT07752407 | Recruiting |
| Potassium-Competitive Acid Blockers (PCABs) | Barrett Esophagus | Phase 4 · NCT07788742 | Recruiting |
| PYTEST® 14C-Urea Breath Test | H Pylori Infection | Phase 4 · NCT07224035 | Completed |
| Water | Healthy Volunteers | Phase 1 · NCT06831344 | Completed |
| Vonoprazan ODT-1 or ODT-2 without Water | Healthy Volunteers | Phase 1 · NCT06831344 | Completed |
Also used in these trials (approved or third-party drugs, not PHAT's own candidates): Amoxicillin, Clarithromycin, Lansoprazole, Midazolam Hydrochloride, Rifampin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
PHAT holds $184.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $45,500/quarter from operations, an estimated runway of 12168.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 32 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PHAT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| James N Topper Director, 10% owner · +17,500 options |
Insider | 6,013,327 | 7.40% | 2026-10-29 |
| BlackRock, Inc. | Institution (13G, 5%+) | 4,378,647 | 5.39% | 2026-06-30 |
| Steven L Basta President and CEO, Director · +401,156 options |
Insider | 373,315 | 0.46% | 2026-02-10 |
| Sanjeev Narula Chief Financial & Bus. Officer · +242,848 options |
Insider | 215,841 | 0.27% | 2026-10-06 |
| Asit Parikh Director |
Insider | 172,622 | 0.21% | 2026-05-22 |
| Frank Karbe Director · +17,500 options |
Insider | 91,622 | 0.11% | 2026-05-19 |
| Anne Marie Cook Chief Legal Off. & Corp. Sec. · +277,878 options |
Insider | 88,660 | 0.11% | 2026-02-10 |
| Robert Charles Breedlove Principal Accounting Officer |
Insider | 67,657 | 0.08% | 2026-09-03 |
| Michael F Cola Director · +17,500 options |
Insider | 63,920 | 0.08% | 2026-05-19 |
| Mark Stenhouse Director · +17,500 options |
Insider | 54,122 | 0.07% | 2026-05-19 |
| Heidi Fields Director · +17,500 options |
Insider | 54,122 | 0.07% | 2026-05-19 |
| Theodore R Schroeder Director |
Insider | 45,122 | 0.06% | 2026-05-19 |
Share count 81,291,520 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PHAT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →